Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome

Rifaximin: An Option for the Treatment of Irritable Bowel Syndrome

Objective: To study the response of irritable bowel syndrome patients presenting with diarrhea and abdominal pain to the treatment with Rifaximin. Study Design: Observational descriptive study. Place and Duration of Study: Study was carried out from 1st February 2019 to 1st December 2019 at Ga...

Full description

Bibliographic Details
Main Author:	Muhammad Abdul Quddus , Arslan Shahzad , Rukhsana Munawar , Khawaja Tahir Maqbool , Amna Mansoor , Naveed Gani , Sheikh Muhammad Taqqi Anwer
Format:	Article
Language:	English
Published:	Riphah International University, Islamabad 2021-12-01
Series:	Journal of Islamic International Medical College
Subjects:	abdominal pain, diarrhea, irritable bowel syndrome, rifaximin.
Online Access:	https://journals.riphah.edu.pk/index.php/jiimc/article/view/1168

Similar Items

Advances in Therapy for Irritable Bowel Syndrome with Diarrhea: Role of Rifaximin in Combination with Metronidazole
by: Arif A Faruqui
Published: (2024-01-01)

Use of Rifaximin in Irritable Bowel Syndrome Treatment
by: Hubert Wróblewski, et al.
Published: (2021-08-01)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
by: Xiaojun Zhuang, et al.
Published: (2020-06-01)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
by: Enzo Vicari, et al.
Published: (2014-10-01)

Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
by: Soldi S, et al.
Published: (2015-12-01)

The efficiency of rifaximin in the correction of the small intestinal bacterial overgrowth syndrome in chronic inflammatory bowel diseases and functional bowel disorders
by: Yu.M. Stepanov, et al.
Published: (2019-11-01)

Rifaximin for Pertuzumab-Related GI Toxicities
by: Aixa E. Soyano, et al.
Published: (2017-08-01)

Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis
by: Alajbegovic Sanjin, et al.
Published: (2012-08-01)

IRRITABLE BOWEL SYNDROME IN CHILDREN AND ADOLESCENTS
by: P.L. Shcherbakov
Published: (2006-01-01)

The Association Between Irritable Bowel Syndrome and Lactose Intolerance
by: Mustafa Reşat DABAK, et al.
Published: (2019-12-01)

Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin
by: Ana L. Sousa, et al.
Published: (2019-08-01)

Impact of crystal polymorphism of rifaximin on dissolution behavior
by: Imen Toukabri, et al.
Published: (2024-03-01)

Review of Pathophysiology and Diagnosis of Irritable Bowel Syndrome
by: Mohammad Reza Ghadir, et al.
Published: (2014-01-01)

Is microscopic colitis a missed diagnosis in diarrhea-predominant Irritable Bowel Syndrome?
by: Hamid Tavakoli, et al.
Published: (2008-08-01)

Use of Bismuth in Irritable Bowel Syndrome
by: T. A. Ilchishina
Published: (2021-10-01)

Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating
by: Kichul Yoon, et al.
Published: (2018-09-01)

Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome
by: Xiaojun Zhuang, et al.
Published: (2018-07-01)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
by: Lacy BE
Published: (2016-02-01)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome: The SEPD perspective
by: Isabel Vera, et al.

Modulation of the microbiota across different intestinal segments by Rifaximin in PI-IBS mice
by: Shengyan Zhang, et al.
Published: (2023-01-01)

Highly Polymorphic Materials and Dissolution Behaviour: The Peculiar Case of Rifaximin
by: Annalisa Bianchera, et al.
Published: (2022-12-01)

EVALUATION OF EFFICACY OF RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH CIRRHOSIS
by: Hafsa Habib, et al.
Published: (2016-12-01)

Serum-derived bovine immunoglobulin for children with diarrhea-predominant irritable bowel syndrome
by: Arrouk R, et al.
Published: (2018-10-01)

Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage
by: Bálint Baráth, et al.
Published: (2022-05-01)

Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial
by: Sabine Becker, et al.
Published: (2024-01-01)

Oral and fecal microbiota in patients with diarrheal irritable bowel syndrome
by: Binbin Tang, et al.
Published: (2023-01-01)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
by: Fragkos KC
Published: (2017-09-01)

Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model
by: Seung Kak Shin, et al.
Published: (2017-11-01)

Evaluation of Levels of Serum IgE and Rectal Mucosal Eosinophilia in Irritable Bowel Syndrome
by: Esra Elif Akkuş, et al.
Published: (2019-08-01)

Peculiarities of Intestine Motor-Evacuation Function in Patients with Various Forms of Irritable Bowel Syndrome
by: S.A. Nagieva, et al.
Published: (2016-04-01)

The effects of rebamipide, sucralfate, and rifaximin against inflammation and apoptosis in radiation-induced murine intestinal injury
by: Won Moon, et al.
Published: (2022-12-01)

Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
by: Kosuke Kaji, et al.
Published: (2020-03-01)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
by: Wang Z, et al.
Published: (2018-12-01)

Role of non-absorbable oral antibiotics in bowel preparation for intracavitary brachytherapy: effects of rifaximin on rectal dosimetric parameters during vaginal cuff brachytherapy
by: Sasan Razmjoo, et al.
Published: (2021-08-01)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
by: Yasuyuki Tamai, et al.
Published: (2021-07-01)

Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives
by: Liu R, et al.
Published: (2020-04-01)

The Effect of Mesalazine on Pain Management in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
by: M Khosravi, et al.
Published: (2022-03-01)

Rifaximin plus norfloxacin versus norfloxacin alone in primary prophylaxis of spontaneous bacterial peritonitis in patients with variceal bleeding
by: Ahmed A Ghafar, et al.
Published: (2019-01-01)

Rifaximin Modifies Gut Microbiota and Attenuates Inflammation in Parkinson’s Disease: Preclinical and Clinical Studies
by: Chien-Tai Hong, et al.
Published: (2022-11-01)